Claudio Dansky Ullmann, MD

Claudio Dansky Ullmann, MD
Chief Medical Officer

Dr. Dansky Ullmann, a 25+-year expert in clinical oncology and pharmaceutical research, is responsible for overseeing clinical development of MaxCyte’s CARMA™ drug development program. Dr. Dansky Ullmann was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where, as part of the executive leadership team, he oversaw all clinical development and operations, shaped corporate strategy, and was directly involved in business development activities as well as investor and analyst interactions. Previously, he was a senior medical director and global clinical lead for oncology clinical research in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before joining Takeda, Dr. Dansky Ullmann worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) as a senior investigator participating in numerous early-phase and late-phase clinical trials. During his career, he also held research roles at the National Institute of Health and held postdoctoral fellowship positions in tumour immunotherapy and drug resistance at the NCI. He also was involved in the development of cell therapies and other immunotherapies at Biomira, Inc. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, University of Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.

Claudio Dansky Ullmann, MD

Dhana Chinnasamy, PhD
Vice President, Non-Clinical and Translational Studies

Dr. Chinnasamy, a 20+-year expert in the research and translation of gene and immunotherapies, oversees all non-clinical and translational activities for MaxCyte’s CARMA platform working closely with the clinical, regulatory, manufacturing, and business development teams in support of MaxCyte’s clinical-stage therapeutic development. Her vast experience includes key roles in bench-to-bedside translational studies on T and NK cell-based therapeutics for the treatment of cancer. Most recently, she led the immuno-oncology team at Precigen/Intrexon where she developed novel T cell products co-expressing chimeric antigen receptors (CARs) and cytokine genes targeting solid tumors. Previously, she served as a Senior Staff Scientist in the Hematology Branch at the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), and as a Senior Research Fellow in the Surgery Branch of the NIH’s National Cancer Institute (NCI).

Claudio Dansky Ullmann, MD

Kathryn Wekselman
Vice President, Regulatory

Dr. Wekselman is a senior drug development expert with extensive experience in drug development, clinical protocol development and execution, and interactions with regulatory authorities, including leading or developing marketing application submissions to the U.S. Food and Drug Administration (FDA), the European Medicines Agency and Health Canada for drugs, biologics and medical devices. She has 11 years of clinical research organization experience as a consultant to pharmaceutical, biotechnology, and device companies, and nine years at Procter & Gamble Pharmaceuticals, where she held positions in medical writing, medical monitoring, and project leadership. Dr. Wekselman earned her BSN (summa cum laude) and PhD in nursing from the University of Cincinnati. She had 10 years of clinical and academic experience in nursing before joining the industry to work in drug development. She has authored more than 25 journal articles or book chapters and has presented more than 30 posters, conference sessions, guest lectures and professional education seminars.

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up